A sample of goings-on in and around the biotech and pharmaceutical industry.
Clinical-stage biopharma Imara has announced the appointment of Willem H. Scheele (photo) as chief medical officer, replacing interim CMO Shi Yin Foo. Before joining Imara, Scheele was executive director, clinician group lead, rare diseases for Pfizer. Previously, he was senior director, global innovative pharma, medicines development for Pfizer.
“Imara is poised for success and I’m confident, through our shared vision and my deep bench of experience in clinical development, we will be able to make great strides in drug development for patients with sickle cell disease and also advance novel programs that enhance fetal hemoglobin, a protein critical in transporting oxygen, for other hemoglobinopathies,” Scheele said.
Nimbus Therapeutics has named Alan Collis vice president of preclinical development. Formerly executive director of DMPK at Forma Therapeutics, Collis joined Nimbus part-time in October 2018. In addition, the company has appointed Jennifer Rocnik vice president, biology. Rocnik, who has more than a dozen years of drug discovery experience in both biotech and pharma, joined Nimbus as director of oncology biology in 2015.
C4 Therapeutics has appointed Adam Crystal chief medical officer. Crystal joins C4 from the Novartis Institutes for BioMedical Research, where he led several early development programs in oncology.
Enterome has announced the appointment of Jan Fagerberg as chief medical officer and Catherine Mathis as chief development officer. Fagerberg has more than 25 years of experience in cancer drug development, having served as chief medical officer at SOTIO and vice president, global development and managing director at Amgen Research GmbH. Mathis was previously COO and head of regulatory affairs at ElsaLys Biotech. She also served for nearly 20 years as head of regulatory affairs at Transgene.
Rubius Therapeutics has named Natalie Holles (photo), president and COO of Audentes Therapeutics, as a member of the company’s board of directors, and Greg Whitehead as senior vice president and chief quality officer. Holles has over 20 years of experience in corporate development, strategic planning and operations leadership. Before joining Audentes, she served as senior vice president, corporate development at Hyperion Therapeutics. Whitehead joins Rubius from bluebird bio, where he most recently served as vice president, quality.
After completing a $23.5 million series A round, Ghent, Belgium-based AgomAb Therapeutics has announced the appointments of Tim Knotnerus as CEO, Torsten Dreier as chief development officer, and John Haurum as chairman of the board of directors. Knotnerus was most recently vice president, corporate development at AM-Pharma; Dreier was cofounder and chief development officer at argenx; and Haurum was most recently CEO of F-star.
Privately held iTeos Therapeutics has announced the appointment of Joanne Jenkins Lager as chief medical officer. Lager joins iTeos from Sanofi, where she served as vice president, head of global oncology development.
Frank D. Lee (photo) has been named CEO of Forma Therapeutics. He succeeds company founder Steve Tregay, who transitions to the role of senior advisor to the CEO. Lee most recently served as senior vice president, global product strategy and therapeutic area head for immunology, ophthalmology and infectious diseases at Genentech.
NGM Biopharmaceuticals has named Hsiao D. Lieu as senior vice president, chief medical officer. Lieu brings 15 years of drug development experience, having most recently served as vice president of early clinical development at Genentech.
Enterprise Therapeutics has appointed Amit D. Munshi as non-executive chairman of the board of directors. Munshi has over 28 years of experience in biopharma management, business development and product development, and currently serves as director, president and CEO of Arena Pharmaceuticals.
Daiichi Sankyo has announced that outgoing CEO George Nakayama will step down in favor of president and COO Sunao Manabe. Nakayama, who delegated the role of president to Manabe two years ago, will remain as chairman of the board of directors.
Flemming Ornskov has been appointed to the supervisory board and has been elected non-executive chairman of Centogene. He most recently served as CEO of Shire and has held senior positions at pharma companies including Bayer, Novartis and Merck.
Mirum Pharmaceuticals has appointed Chris Peetz as CEO, succeeding Mike Grey, who will stay on with Mirum in the role of executive chairman of the board of directors. Peetz was appointed as Mirum’s president and a board member at the company’s founding last year. He previously served as CFO and head of corporate development at Tobira Therapeutics.
CAR-T therapies developer Celyad has named Filippo Petti as CEO. He was previously the company’s CFO and before joining Celyad served as a healthcare investment banker at Wells Fargo Securities and William Blair & Company.
Lloyd Sanders has joined Epic Sciences as president and CEO, succeeding Murali Prahalad who, after serving nearly six years in the role, has stepped down to pursue new opportunities and has been appointed to Epic’s board of directors. Sanders has 20 years of diagnostics and pharma industry experience, most recently serving as president of Myriad Genetics’ oncology division. Previously, he was COO at Dey Pharma, a division of Mylan.